JPRN-UMIN000002418已完成1 期
Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial - Combination chemotherapy of sorafenib and S-1 in patients with advanced hepatocellular carcinoma: phase I trial
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) histrogically confirmed combined type hepatocellular carcinoma or sarcomatous change 2) previous therapy for hepatocellular carcinoma within 30 days 3) preceded chemotherapy used sorafenib or 5-FU (excluded transcatheter arterial embolization or adjuvant chemotherapy) 4) inadequate for administration of sorafenib or S-1 5) active double cancer 6) active infection (excluded viral hepatitis) 7) water diarrhea 8) severe complication 9) refractory ascites of pleural effusion 10) metastases to central nervous system 11) pregnancy or lactaing females 12) inappropriate for entry onto this study in the judgment of the investigator
研究者
相似试验
已完成
2 期
Investigating the role of targeted therapy Sorafenib - the Fms-like tyrosine kinase 3 (FLT3) inhibitor, in combination with intensive chemotherapy, for previously untreated adult patients with Acute Myeloid Leukaemia (AML) with FLT3 mutations. A Phase II randomised placebo-controlled multi-centre studyPreviously untreated adult acute myeloid leukaemia (AML) with FLT3-ITD mutation.Cancer - Leukaemia - Acute leukaemiaACTRN12611001112954eukaemia Foundation of Australia98
招募中
1 期
A phase I study of sorafenib/UFT chemotherapy in advanced hepatocellular carcinomaadvanced hepatocellular carcinomaJPRN-UMIN000005335Kyushu Univrsity Hospital18
已完成
1 期
A phase 1 study of TS-1 and sorafenib combination therapy in patients with advanced hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000002590Chiba University Hospital24
已完成
2 期
Phase II study of sorafenib with S-1 for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000007199Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University25
已完成
不适用
Pilot Study of the combination of sorafenib and fractionated irinotecan in pediatric relapse/refractory hepatic cancerJPRN-UMIN000021931Kanagawa children's medical center12